Novavax, Inc. (NASDAQ:NVAX) Receives $204.86 Consensus Target Price from Brokerages

Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target […]

Related Keywords

,Johna Herrmann ,Gregorym Glenn ,Securities Exchange Commission ,Lord Abbett ,Nasdaq ,Connor Clark Lunn Investment Management Ltd ,Ikarian Capital ,Jpmorgan Chase Co ,Cantor Fitzgerald ,Novavax Company Profile Get Rating ,Novavax Inc ,Get Rating ,Marketbeat Ratings ,Exchange Commission ,World Investors ,Street Corp ,Connor Clark ,Lunn Investment Management ,Company Profile ,Middle East ,Novavax ,Nasdaq Nvax ,Nvax ,Medical ,67000210 ,Ratings ,Consensus ,